{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:22:00Z","timestamp":1778631720747,"version":"3.51.4"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Lo Kwee Seong Biomedical Research Fund"},{"name":"Direct Grant from the Chinese University of Hong Kong"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jpsychires.2018.12.015","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T09:13:24Z","timestamp":1544778804000},"page":"83-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders"],"prefix":"10.1016","volume":"110","author":[{"given":"Hon-Cheong","family":"So","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui-Hang","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2018.12.015_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coph.2007.12.002","article-title":"Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders","volume":"8","author":"Abe","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-1110-1","article-title":"New insights into the generation and role of de novo mutations in health and disease","volume":"17","author":"Acuna-Hidalgo","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib5","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib6","first-page":"11","article-title":"Comorbid behavioral problems and psychiatric disorders in autism spectrum disorders","volume":"2","author":"Belardinelli","year":"2016","journal-title":"J. Child. Develop. Dis."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate - a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. Royal Statist. Soc. Ser. B-Methodol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1037\/0022-006X.62.1.17","article-title":"Epidemiology and prevalence of psychopathology in people with mental retardation","volume":"62","author":"Borthwick-Duffy","year":"1994","journal-title":"J. Consult. Clin. Psychol."},{"issue":"Pt 5","key":"10.1016\/j.jpsychires.2018.12.015_bib9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1365-2788.2000.00270.x","article-title":"Epilepsy and intellectual disability","volume":"44","author":"Bowley","year":"2000","journal-title":"J. Intellect. Disabil. Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MOL.0b013e3283453e41","article-title":"Mechanisms for the anti-inflammatory effects of statins","volume":"22","author":"Bu","year":"2011","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","article-title":"Psychiatric comorbidities and schizophrenia","volume":"35","author":"Buckley","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbu016","article-title":"Genetic relationships between schizophrenia, bipolar disorder, and schizoaffective disorder","volume":"40","author":"Cardno","year":"2014","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/med.20084","article-title":"Competitive AMPA receptor antagonists","volume":"27","author":"Catarzi","year":"2007","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib14","series-title":"Epigenetics in Psychiatry","first-page":"515","article-title":"Histone deacetylase inhibitors and psychiatric disorders","author":"Chakravarty","year":"2014"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-9338(14)78635-3","article-title":"Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study","volume":"29","author":"Chaudhry","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/hmg\/7.1.109","article-title":"In vitro reactivation of the FMR1 gene involved in fragile X syndrome","volume":"7","author":"Chiurazzi","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/hmg\/8.12.2317","article-title":"Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene","volume":"8","author":"Chiurazzi","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tig.2016.01.001","article-title":"Autism and cancer share risk genes, pathways, and drug targets","volume":"32","author":"Crawley","year":"2016","journal-title":"Trends Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/aur.208","article-title":"Autism and cancer risk","volume":"4","author":"Crespi","year":"2011","journal-title":"Autism Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bmc.2013.11.025","article-title":"Retinoic acid signaling pathways in development and diseases","volume":"22","author":"Das","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004219","article-title":"MAGMA: generalized gene-set analysis of GWAS data","volume":"11","author":"de Leeuw","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrg.2016.29","article-title":"The statistical properties of gene-set analysis","volume":"17","author":"de Leeuw","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.febslet.2011.05.004","article-title":"Are retinoids potential therapeutic agents in disorders of social cognition including autism?","volume":"585","author":"Ebstein","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13668250.2011.572548","article-title":"Comorbidity of intellectual disability and mental disorder in children and adolescents: a systematic review","volume":"36","author":"Einfeld","year":"2011","journal-title":"J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib27","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1212\/WNL.0b013e31827b1ae0","article-title":"Depression in epilepsy: a systematic review and meta-analysis","volume":"80","author":"Fiest","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib28","article-title":"Aggression in autism spectrum disorder: presentation and treatment options","volume":"12","author":"Fitzpatrick","year":"2016","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.tig.2018.04.004","article-title":"Genetic-driven druggable target identification and validation","volume":"34","author":"Floris","year":"2018","journal-title":"Trends Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib30","series-title":"Pathways Analyses of Schizophrenia GWAS Focusing on Known and Novel Drug Targets","author":"Gaspar","year":"2016"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib31","doi-asserted-by":"crossref","first-page":"D1100","DOI":"10.1093\/nar\/gkr777","article-title":"ChEMBL: a large-scale bioactivity database for drug discovery","volume":"40","author":"Gaulton","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib32","doi-asserted-by":"crossref","DOI":"10.1186\/gm372","article-title":"De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention","volume":"4","author":"Gauthier","year":"2012","journal-title":"Genome Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/A:1016330802348","article-title":"Depression in persons with autism: implications for research and clinical care","volume":"32","author":"Ghaziuddin","year":"2002","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1124\/mol.109.061333","article-title":"Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?","volume":"77","author":"Grayson","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib35","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1177\/0883073815601501","article-title":"Autism spectrum disorder and epilepsy: two sides of the same coin?","volume":"30","author":"Jeste","year":"2015","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/acps.12644","article-title":"Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review","volume":"135","author":"Jobski","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib37","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nrd2681","article-title":"Therapeutic application of histone deacetylase inhibitors for central nervous system disorders","volume":"7","author":"Kazantsev","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib38","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib39","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00002018-199005060-00002","article-title":"Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide","volume":"5","author":"Kim","year":"1990","journal-title":"Drug Saf."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib40","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib42","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1126\/science.279.5352.863","article-title":"Impaired locomotion and dopamine signaling in retinoid receptor mutant mice","volume":"279","author":"Krezel","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/msb.2009.98","article-title":"A side effect resource to capture phenotypic effects of drugs","volume":"6","author":"Kuhn","year":"2010","journal-title":"Mol. Syst. Biol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib44","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/mp.2014.33","article-title":"Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age","volume":"20","author":"Kulkarni","year":"2015","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1126\/science.1132939","article-title":"The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease","volume":"313","author":"Lamb","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib46","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib47","article-title":"Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs","volume":"45","author":"Lee","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31806450da","article-title":"Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial","volume":"31","author":"Lerner","year":"2008","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib49","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4088\/JCP.12m08160","article-title":"The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial","volume":"74","author":"Lerner","year":"2013","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib50","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-016-0316-9","article-title":"Targeting retinoid receptors to treat schizophrenia: rationale and progress to date","volume":"30","author":"Lerner","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib51","article-title":"Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database (vol 21, pg 290, 2016)","volume":"21","author":"Li","year":"2016","journal-title":"Mol. Psychiatr."},{"issue":"Suppl. 4","key":"10.1016\/j.jpsychires.2018.12.015_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/PL00010704","article-title":"Psychiatric symptoms in children with intellectual disability","volume":"8","author":"Linna","year":"1999","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib53","doi-asserted-by":"crossref","first-page":"145","DOI":"10.5582\/irdr.2016.01048","article-title":"Fragile X syndrome: a review of clinical management","volume":"5","author":"Lozano","year":"2016","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib54","article-title":"Multi-target drugs: the trend of drug research and development","volume":"7","author":"Lu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrn2212","article-title":"Retinoic acid in the development, regeneration and maintenance of the nervous system","volume":"8","author":"Maden","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib56","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.psychres.2012.05.036","article-title":"Altered immune function in unaffected first-degree biological relatives of schizophrenia patients","volume":"200","author":"Martinez-Gras","year":"2012","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1289\/ehp.6028","article-title":"The comparative Toxicogenomics database (CTD)","volume":"111","author":"Mattingly","year":"2003","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib58","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jchemneu.2011.02.002","article-title":"Estrogen receptors stimulate brain region specific metabotropic glutamate receptors to rapidly initiate signal transduction pathways","volume":"42","author":"Meitzen","year":"2011","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib60","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib61","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1192\/bjp.bp.111.105551","article-title":"Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality","volume":"200","author":"Owen","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.jpsychires.2018.12.015_bib63","first-page":"17","article-title":"Pharmacology of valproate","volume":"37","author":"Owens","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12017-013-8285-3","article-title":"Epigenetic mechanisms of rubinstein-taybi syndrome","volume":"16","author":"Park","year":"2014","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib65","first-page":"165","article-title":"Psychiatric illness and psychotropic medication use in epilepsy","volume":"vol. 16","author":"Perr","year":"2011"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib66","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pnpbp.2016.09.002","article-title":"Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases","volume":"72","author":"Qiu","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib67","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib68","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.179.6.523","article-title":"Long-term affective disorder in people with mild learning disability","volume":"179","author":"Richards","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib69","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","article-title":"The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?","volume":"64","author":"Rosenberg","year":"2007","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib70","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach","volume":"3","author":"Ruderfer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib71","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib72","doi-asserted-by":"crossref","first-page":"14349","DOI":"10.1073\/pnas.94.26.14349","article-title":"Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family","volume":"94","author":"Samad","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib73","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jne.12034","article-title":"Oestradiol modulation of serotonin reuptake transporter and serotonin metabolism in the brain of monkeys","volume":"25","author":"Sanchez","year":"2013","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib74","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/epi.13769","article-title":"Anxiety and depressive disorders in people with epilepsy: a meta-analysis","volume":"58","author":"Scott","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib76","first-page":"1","article-title":"Translating GWAS findings into therapies for depression and anxiety disorders: gene-set analyses reveal enrichment of psychiatric drug classes and implications for drug repositioning","author":"So","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib77","first-page":"1","article-title":"Exploring shared genetic bases and causal relationships of schizophrenia and bipolar disorder with 28 cardiovascular and metabolic traits","author":"So","year":"2018","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib78","first-page":"1","article-title":"Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia","author":"Solmi","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib79","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4088\/JCP.v65n0601","article-title":"Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels","volume":"65","author":"Stahl","year":"2004","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib80","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.tcm.2016.08.008","article-title":"Leveraging human genetics to guide drug target discovery","volume":"27","author":"Stitziel","year":"2017","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib81","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1214\/aos\/1074290335","article-title":"The positive false discovery rate: a Bayesian interpretation and the q-value","volume":"31","author":"Storey","year":"2003","journal-title":"Ann. Stat."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/npp.2008.158","article-title":"Targeting AMPA and kainate receptors in neurological disease: therapies on the horizon?","volume":"34","author":"Swanson","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib83","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10803-012-1617-6","article-title":"Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study","volume":"43","author":"Tsiouris","year":"2013","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib84","doi-asserted-by":"crossref","first-page":"D804","DOI":"10.1093\/nar\/gkw865","article-title":"denovo-db: a compendium of human de novo variants","volume":"45","author":"Turner","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib85","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrg3241","article-title":"Applications of next-generation sequencing de novo mutations in human genetic disease","volume":"13","author":"Veltman","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib86","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.schres.2014.08.021","article-title":"A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism","volume":"159","author":"Vincenzi","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib87","article-title":"Valproate for schizophrenia","volume":"3","author":"Wang","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib88","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/amiajnl-2012-001431","article-title":"Development and evaluation of an ensemble resource linking medications to their indications","volume":"20","author":"Wei","year":"2013","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib89","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4155\/fmc.13.141","article-title":"Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia","volume":"5","author":"Weiwer","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib90","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cpr.2009.01.003","article-title":"Anxiety in children and adolescents with autism spectrum disorders","volume":"29","author":"White","year":"2009","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib91","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1017\/S1461145710000866","article-title":"Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective","volume":"13","author":"Wong","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib92","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.euroneuro.2016.11.012","article-title":"Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials","volume":"27","author":"Xiang","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib93","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4236\/nm.2012.31016","article-title":"Valproic acid, a drug with multiple molecular targets related to its potential neuroprotective action","volume":"3","author":"Ximenes","year":"2012","journal-title":"Neurosci. Med."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib94","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0161-813X(03)00051-2","article-title":"[3H]Ethynylbicycloorthobenzoate ([3H]EBOB) binding in recombinant GABAA receptors","volume":"24","author":"Yagle","year":"2003","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.jpsychires.2018.12.015_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081689","article-title":"New targets for schizophrenia treatment beyond the dopamine hypothesis","volume":"18","author":"Yang","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib96","doi-asserted-by":"crossref","first-page":"D1069","DOI":"10.1093\/nar\/gkv1230","article-title":"Therapeutic target database update 2016: enriched resource for bench to clinical drug target and targeted pathway information","volume":"44","author":"Yang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpsychires.2018.12.015_bib97","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","article-title":"DSigDB: drug signatures database for gene set analysis","volume":"31","author":"Yoo","year":"2015","journal-title":"Bioinformatics"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618308732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395618308732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:12:35Z","timestamp":1758366755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395618308732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":97,"alternative-id":["S0022395618308732"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.12.015","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/173641","asserted-by":"object"}]},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2018.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}